Navigation Links
Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
Date:4/4/2011

MOUNTAIN VIEW, Calif., April 4, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced long-term data that demonstrated patients treated with the investigational drug QNEXA® for two years showed reductions in blood pressure and the use of antihypertensive medications as well as improvements in lipid levels following significant reductions in weight loss as compared to those in the placebo group over two years.

The data – additional results from the SEQUEL study – were presented Sunday at the 60th Annual Scientific Meeting of The American College of Cardiology by Michael Davidson, M.D., clinical professor and director of preventive cardiology at The University of Chicago.

Specific results are as follows:

  • Patients on QNEXA had significant reductions in weight loss as compared to those in the placebo group over two years. Least-squares mean percent weight loss at week 108 was -9.3% and -10.5%, respectively, for the mid and top dose as compared to -1.8% for the placebo group.
  • Overall, patients taking QNEXA showed a significant reduction in the number of antihypertensive medications they required as compared to those taking a placebo over two years of treatment.
  • Specifically, patients with hypertension at the beginning of the study taking QNEXA mid and top dose showed a significant reduction in the number of antihypertensive medications they required of -9.8% and -18.9%, respectively, while patients taking a placebo showed a net increase of +4.2%.
  • Dyslipidemic patients at baseline treated with the mid and top dose of QNEXA had decreases in triglycerides of -25.9% and -26.3%, respectively, as compared to -14.3% for the placebo group.
  • Dyslipidemic patients at baseline treated with the mid and top dose of QNEXA had improvements in HDL-C of +11.4% and +16.7%, respectively, as c
    '/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
2. Medizone Internationals Mass-Market Sterilization Technology to be Produced by Canadian Medical Device Heavyweights
3. The Spatz Adjustable Balloon System® for Weight Loss Becomes the First Intragastric Balloon to Receive Regulatory Approval for 1 Year Implantation Time
4. Results of Innovative Clinical Study Show New Combination for Weight Loss Success
5. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
6. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
7. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
8. The Results are in: Users of BodyMedias Wearable Body-Monitoring Technology Lose 3 Times More Weight
9. ReShape Medical Announces Initiation of U.S. Clinical Study for Weight Loss
10. Womens Digital Imaging Using DXA Total Body Fat Analysis to Help Patients in Weight Management and Fitness Programs
11. New Survey Shows Seniors Struggle Under the Weight of Multiple Medication Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Blueprint Medicines today announced ... and potent inhibitor of fibroblast growth factor receptor ... of hepatocellular carcinoma (HCC) that are dependent on ... induced complete tumor regression in a subset of ... at the highest dose levels. These data will ...
(Date:4/23/2015)... S.C. , April 23, 2015 Once ... and strengthening our commitment to patient safety. ... the fight against infectious disease. The next ... Medical gas sensors are now mounted in the ... the need to open ceiling tiles potentially releasing dust ...
(Date:4/23/2015)... 2015  Research Solutions, Inc. (OTCQB: RSSS), a pioneer in ... information for life science companies, academic institutions, and other ... the 16 th Annual B. Riley & Co. ... the Loews Hollywood Hotel in ... management is scheduled to present on Tuesday, May 12 ...
Breaking Medicine Technology:Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3BeaconMedaes launches new Zone Valve Box Assembly 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 3
... Jan. 23, 2012  B. Braun Medical Inc. (B. Braun), a ... received U.S. Food and Drug Administration (FDA) approval for ... B. Braun,s DUPLEX® Drug Delivery System . The ... an FDA-approved 2g Cefazolin dose to hospitals and other healthcare ...
... Jan. 23, 2012 ThermoGenesis Corp. (NASDAQ: KOOL ... process and store adult stem cells, said today, it had ... from a new public cord blood bank that will begin ... Services, a national charitable organization that manages the supply of ...
Cached Medicine Technology:B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 3Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 2Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 3Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 4
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
(Date:4/24/2015)... Olive Fertility Centre is proud to ... co-director, has been honoured for his pioneering work in ... Hope Gala. , “We are very pleased to ... has been at the forefront of fertility research and ... Executive Director of Fertile Futures--a Canadian non-profit organization that ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... Opera ” was featured on NewsWatch as part of its ... products available to consumers. Andrew Tropeano, a technology expert and ... viewers how this is the fastest way to surf the ... be in existence. But each web browser is slightly different ... Celebrating their 20th anniversary this year, Opera connects over 350 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... ValueOptions(R), Inc., the nation,s largest independent behavioral ... entered into an agreement with CareIntegra to provide ... its core product offerings. (Logo: ... CareIntegra and ValueOptions(R) will collaborate to develop and ...
... Va., Jan. 7 CEL-SCI Corporation (NYSE Alternext ... announced today the initiation of a definitive study of ... the long-lasting beneficial effects on animals with the disease. ... a large pharmaceutical company which is evaluating the possibility ...
... ORLEANS, Jan. 7 Jones Walker is pleased to announce ... an Order of the British Crown that has been in ... in the New Orleans office of Jones Walker, was recently ... Hamilton, a Partner in the firm,s Mobile and Washington offices, ...
... Virginia, January 7 Ekahau Inc., a leading,provider ... announced,that after a competitive bid process it was ... to provide the Ekahau Real Time,Location System (RTLS) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a ) , ...
... shownOAKBROOK TERRACE, Ill., Jan. 7 Even though nurses ... study published in the January 2009 issue of ... shows that nurses often are not included when ... such a hands-on role at the bedside of their ...
... Atlanta-based Billian Publishing, Inc.,owners of Billian,s HealthDATA, announced ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070925/BILLIANSLOGO ) ... founded in 1989 just as the information technology,industry ... Since then, new,and established companies have contracted with ...
Cached Medicine News:Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 3Health News:Jones Walker Attorneys Named to Positions in Order of British Crown 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 3Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 2Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 3Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
Focus Dailies Toric are the first daily disposable lens for astigmatism...
Frequency 55 Toric XR is a great option for those with high levels of astigmatism...
Medicine Products: